Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271653 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL18378763 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL10347198 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL13797804 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL15796773 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL5271657 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL4679055 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL4206354 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL18378981 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 | |
| SCHEMBL214490 | 1.00 | NAAA (0.55) | NAAAEPHX1TSHRHTR2CHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-2472255-B1 | SEPARATING AGENT FOR OPTICAL ISOMER | DAICEL CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2708524-B1 | Polyisocyanide derivative having controlled helical main chain structure | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-102667466-B | Separating agent for optical isomer | DAICEL CHEM | 2014-09-10 | — | — | CN | disclosed |
| EP-2708524-A1 | Polyisocyanide derivative having controlled helical main chain structure | Japan Science and Technology Agency (JP) | 2014-03-19 | — | — | EP | disclosed |
| EP-1956035-B1 | POLYISOCYANIDE DERIVATIVE HAVING CONTROLLED HELICAL MAIN CHAIN STRUCTURE | JAPAN SCIENCE & TECH AGENCY (JP) | 2014-01-22 | — | — | EP | disclosed |
| CN-102667466-A | Separating agent for optical isomer | DAICEL CHEM | 2012-09-12 | — | — | CN | disclosed |
| EP-2472255-A1 | SEPARATING AGENT FOR OPTICAL ISOMER | Daicel Corporation (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149851-A1 | SEPARATING AGENT FOR OPTICAL ISOMERS | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2012-06-14 | — | — | US | disclosed |
| US-7619109-B2 | Polyisocyanide derivative having controlled helical main chain structure | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619109-B2 | Polyisocyanide derivative having controlled helical main chain structure | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090030227-A1 | Polyisocyanide Derivative Having Controlled Helical Main Chain Structure | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090030227-A1 | Polyisocyanide Derivative Having Controlled Helical Main Chain Structure | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1956035-A1 | POLYISOCYANIDE DERIVATIVE HAVING CONTROLLED HELICAL MAIN CHAIN STRUCTURE | Japan Science and Technology Agency (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030227-A1 | Polyisocyanide Derivative Having Controlled Helical Main Chain Structure | PARG, PAH, PARN | NAAA 2576/4885EPHX1 3108/4885TSHR 4748/4885 |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | NAAA 2562/4885EPHX1 1532/4885TSHR 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.